MDB Share Price Performance
zł0.64
0.12 (23.74%)
Price zł0.64
Share Pricezł0.64
Medicofarma Biotech SA Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
MDB Community Narratives
There are no narratives available yet.
Recent MDB News & Updates
Medicofarma Biotech SA Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.047
- Gross Margin
- -454.29%
- Net Profit Margin
- -1,148.27%
- Debt/Equity Ratio
- 57.1%
Medicofarma Biotech SA Competitors
Snowflake Analysis
About MDB
- Founded
- 2001
- Employees
- 15
- CEO
- WebsiteView website
Medicofarma Biotech SA, a biotechnology company, provides medicines, medicinal products, and biotechnology products. The company is involved in the research and development works in collaboration with pharmaceutical and cosmetic manufacturing plants, as well as research units. It also offers staff support and equipment during the early stages of development of generic pharmaceutical products and cosmetics; and covid-19 test kits, such as real time PCR genetic tests. The company was formerly known as Inbook Spólka Akcyjna. Medicofarma Biotech SA was founded in 2001 and is headquartered in Warsaw, Poland. Medicofarma Biotech SA operates as a subsidiary of Vitama Spolka Akcyjna
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Polish Market Performance
- 7 Days: 0.2%
- 3 Months: 0.4%
- 1 Year: 24.7%
- Year to Date: 27.1%
Over the last 7 days, the market has remained flat, although notably the Materials sector gained 8.2% in that time. More promisingly, the market is up 25% over the past year. Looking forward, earnings are forecast to grow by 16% annually. Market details ›